American Society of Hirudotherapy

Whitmantides A-C

First D-leucine-containing linear peptides discovered in any leech — Zhang 2019 demonstrates neuroprotection in oxygen-glucose deprivation Neuro-2a model with high serum stability.

Preclinical / mechanisticLast updated: 2026-05-27 · Reviewed by ASH Editorial Board
Molecular weight of Whitmantides A-C compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaWhitmantides A-C1.2 kDa
Molecular weight (kilodaltons) of Whitmantides A-C (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
First D-leucine-containing linear peptides discovered in any leech — Zhang 2019 demonstrates neuroprotection in oxygen-glucose deprivation Neuro-2a model with high serum stability.
Evidence level
In vitro
Drug vs leech
Purified natural compound

Clinical translation limit

Whitmantides A-C's in vitro neuroprotection against oxygen-glucose deprivation does NOT establish clinical efficacy. No FDA-approved derivative exists; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Molecular weight
1,200 Da
Source species
Whitmania pigra
Discovered
2019 · Zhang ZY et al.
Whitmantides A-C molecular structure

Biological Targets

  • neuroprotective pathways (oxygen-glucose deprivation / reperfusion injury); D-leucine confers protease resistance

Key Citations

  1. Zhang ZY et al. (2019), J Nat Prod · PMID 31361480

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.